Menlo Park-based biotech company, Fundamental Applied Biology (FAB) announced that it received $21 million in second round funding with Daniel S. Gold as the new CEO.

FAB is built on technology developed by Stanford professor, James R. Swartz. Dr. Swartz’s protein synthesis technology is a departure from current technique where protein replication used for industrial means (such as medicine) is made by an actual cell; a process that is slow and plagued with inefficiencies. His technology allows proteins to be made outside the cell, improving production time, yield and purity.


Investors can expect biotech companies that utilize such systems to produce medication with lower production cost and faster turn around time to better respond to market demands.